bimzelx
ucb pharma s.a. - bimekizumab - psoriasis - Ónæmisbælandi lyf - plaque psoriasisbimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisbimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)bimzelx is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)bimzelx is indicated for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.
cibinqo
pfizer europe ma eeig - abrocitinib - dermatitis, atópísk - aðrar húðsjúkdómar - cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.
famvir filmuhúðuð tafla 125 mg
phoenix labs - famciclovirum inn - filmuhúðuð tafla - 125 mg
prednisolon actavis tafla 10 mg
actavis group ptc ehf. - prednisolone - tafla - 10 mg
monoprost augndropar, lausn í stakskammtaíláti 50 míkróg/ml
laboratoires thea* - latanoprostum inn - augndropar, lausn í stakskammtaíláti - 50 míkróg/ml
decortin h tafla 5 mg
merck ab - prednisolonum inn - tafla - 5 mg
depo-medrol stungulyf, dreifa 40 mg/ml
pfizer aps - methylprednisolonum acetat - stungulyf, dreifa - 40 mg/ml
diprospan stungulyf, dreifa 5+2 mg/ml
n.v. organon* - betamethasonum dínatríumfosfat; betamethasonum díprópíónat - stungulyf, dreifa - 5+2 mg/ml
fixopost (monoprostduo) augndropar, lausn í stakskammtaíláti 50 míkróg/ml + 5 mg/ml
laboratoires thea* - latanoprostum inn; timololum maleat - augndropar, lausn í stakskammtaíláti - 50 míkróg/ml + 5 mg/ml
latanoprost actavis augndropar, lausn 50 míkróg/ml
actavis group ptc ehf. - latanoprostum inn - augndropar, lausn - 50 míkróg/ml